Nonsyndromic Malignant Hyperthermia Susceptibility.
Riazi S, Biesecker LG, Rosenberg H, Dirksen RT.
Riazi S, et al.
2003 Dec 19 [updated 2025 Aug 7]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.
2003 Dec 19 [updated 2025 Aug 7]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.
PMID: 20301325
Free Books & Documents.
Review.
CLINICAL CHARACTERISTICS: Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated with uncontrolled skeletal muscle hypermetabolism. ...DIAGNOSIS/TESTING: The diagnosis of MHS is established with in …
CLINICAL CHARACTERISTICS: Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal muscle calcium regula …